AbbVie Inc. (ABBV) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 10:40 AM EDT
Company Participants
Robert Michael – CEO & Chairman of the Board
Roopal Thakkar – Executive VP of Research & Development and Chief Scientific Officer
Scott Reents – Executive VP & CFO
Conference Call Participants
Asad Haider – Goldman Sachs Group, Inc., Research Division
Presentation
Asad Haider
Goldman Sachs Group, Inc., Research Division
All right. We’re just about at time. So we can kick off our next session with AbbVie. Very excited to have the whole AbbVie management team over here with us. Rob Michael, CEO; Scott Reents, CFO; and Roopal Thakkar, CSO. Thank you all for being with us today.
Robert Michael
CEO & Chairman of the Board
Great to be with you.
Roopal Thakkar
Executive VP of Research & Development and Chief Scientific Officer
Thank you.
Question-and-Answer Session
Asad Haider
Goldman Sachs Group, Inc., Research Division
So Rob, maybe starting with you with a big picture question. Just to sort of like, high level, frame for us where AbbVie sits today as we look out to the next 5 to 10 years, how do you expect the complexion of the company to evolve with respect to therapeutic areas, business lines and potential new pillars of growth?
Robert Michael
CEO & Chairman of the Board
Like I think what you’re seeing is a continuation of the strategy where we’ve talked about a quick return to growth. We exceeded our peak sales last year, just 2 years after the U.S. HUMIRA LOE with, I’d say, like 4 really like strong growth drivers for the company. Immunology, clearly, I mean, SKYRIZI and RINVOQ
[Audio Gap]
the potential that we
[Audio Gap]
time, right? And so — and we see significant runway for that. I’d say in oncology, and I’ll actually have Roopal speak to